BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32164276)

  • 1. Precision Medicine Management of Chronic Lymphocytic Leukemia.
    Moia R; Patriarca A; Schipani M; Ferri V; Favini C; Sagiraju S; Al Essa W; Gaidano G
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
    Moia R; Patriarca A; Schipani M; Gaidano G
    Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostication in chronic lymphocytic leukemia.
    Moia R; Gaidano G
    Semin Hematol; 2024 Apr; 61(2):83-90. PubMed ID: 38523019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic lymphocytic leukemia: update on pathophysiology and management].
    Suzumiya J
    Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
    Cohen JA; Bomben R; Pozzo F; Tissino E; Härzschel A; Hartmann TN; Zucchetto A; Gattei V
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting p53 in chronic lymphocytic leukemia.
    Moia R; Boggione P; Mahmoud AM; Kodipad AA; Adhinaveni R; Sagiraju S; Patriarca A; Gaidano G
    Expert Opin Ther Targets; 2020 Dec; 24(12):1239-1250. PubMed ID: 33016796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
    Gaidano G; Rossi D
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
    Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
    Front Oncol; 2019; 9():689. PubMed ID: 31555576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
    Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic lymphocytic leukemia. Treatment and genetic risk profile].
    Stilgenbauer S; Hallek M
    Internist (Berl); 2013 Feb; 54(2):164, 166-70. PubMed ID: 23371259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
    Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
    Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS; Stilgenbauer S
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
    Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
    J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.